The FDA has approved Novo Nordisk’s Ozempic—once-weekly semaglutide—for an expanded indication of CV risk reduction in people with type 2 diabetes and established heart disease.

Data released by the Centers for Disease Control and Prevention on Jan. 14 revealed that one in six cases of vaping-related lung illness, or EVALI, can be linked to legally purchased cannabis products.

Women’s blood vessels age at a faster rate than men’s, researchers from the Smidt Heart Institute at Cedars-Sinai reported this month—a finding that could explain some of the considerable sex gaps in CVD in men and women.

A cross-structural analysis published in Mayo Clinic Proceedings this January independently links diabetes to the development of heart failure, suggesting diabetic cardiomyopathy is a real—and growing—issue in the U.S.

One Minneapolis cardiologist is concerned that people following the trendy Keto diet aren’t worrying enough about their fat intake.

Redesigning the artificial heart valve could improve blood flow and potentially eliminate the need for blood thinners in patients with mechanical support, according to a new study.

Amarin on Jan. 13 announced the launch of True to Your Heart, a new educational campaign geared toward heart patients who remain at a persistent risk for CVD despite being treated with statins and other standard-of-care therapies.

Pharmaceutical company Novartis has partnered with the U.K.’s National Health Service to study inclisiran, an investigational cholesterol-lowering drug that experts project could save 30,000 lives over the next decade.